Phase 2 N=92 Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Dose Limiting Toxicity (Phase 1 Only) — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,025 A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
Poliomyelitis
Primary: Serious Adverse Reactions (SARs), Severe AEs and Important Medical Reactions (IMRs) Incidence — 0; 1; 0; 5 participants
Phase 2 N=139 Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Median Progression-free Survival (PFS) — 11; 13 Months — p=0.07
Phase 2 N=1,053 A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose — 0; 1; 0; 0 Participants
Phase 2 N=72 A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COVID · Covid-19 · Coronavirus
Primary: Number of Subjects Who Experienced Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 23; 22; 1 Participants
Phase 2 N=181 Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
HIV Infections
Primary: Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) — 4.3; 8.7; 6.7; 29.4 percentage of participants
Phase 2 N=15 Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Total Number of Adverse Events and Serious Adverse Events — 27; 15; 8; 4 count of events
Phase 2 N=42 A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Coronavirus Infections
Primary: Measurement of the Change in Oxygen Requirement From Baseline — -38.8; -33.0 L/min*day
Phase 2 N=4 Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
Alpha1-Antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4 Participants
Phase 2 N=26 Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Kidney Cancer
Primary: Best Response as Measured by CT, Bone Scans, and Clinical Progression — 1; 0; 0; 1 Participants
Phase 2 N=24 Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response
Asthma
Primary: Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14 — -0.53…
Phase 2 N=80 Brexpiprazole in Borderline Personality Disorder
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder — 14.9; 14.9; 7.6; 6.7 score on a scale
Phase 2 N=235 TD-0903 for ALI Associated With COVID-19
Acute Lung Injury (ALI) Associated With COVID-19 · Lung Inflammation Associated With COVID-19
Primary: Part 2: Number of Respiratory Failure-free Days (RFDs) From Randomization to Day 28 — 21.0; 21.0 days — p=0.6137
Phase 2 N=181 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Covid19
Primary: Change From Baseline to Day 8 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Shedding — -2.88; -3.52; -3.75; -3.03 log10 copies/ml — p=0.4829
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants